Eosinophils sub-types in patients with severe asthma treated with monoclonal antibodies. - Milan 2023

Biological treatments for asthma: novel real-life insights

Chair(s): Nicolas Roche, Simon Lea

Session type: Poster session

Eosinophils sub-types in patients with severe asthma treated with monoclonal antibodies.

Alejandra Sanchez-Santos

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

BIOLOGIC TREATMENT IN PERSISTENT SEVERE ASTHMA

Edurne Echevarria Guerrero

Poster

Abstract

Eosinophils sub-types in patients with severe asthma treated with monoclonal antibodies.

Alejandra Sanchez-santos

Poster

Abstract

Phenotypical distribution according to the age of asthma onset in patients evaluated for biologic therapy prescription in a referral center in Colombia

Abraham Ali Munive

Poster

Abstract

Asthma control in severe asthma patients treated with tezepelumab: A prospective, observational, real-world evidence study in Europe and Canada (ASCENT)

Katrin Milger-kneidinger

Poster

Abstract

Success of an oral corticosteroid withdrawal pathway for severe asthma patients on biologics

Richard Russell

Poster

Abstract

On-treatment clinical remission with tezepelumab in patients with severe, uncontrolled asthma in the phase 3 DESTINATION study

Michael E. Wechsler

Poster

Abstract

Real-world experience of biologics use and switching among adults with severe asthma at a tertiary care centre in United Arab Emirates

Yasser Alkassar

Poster

Abstract

Long-term safety and efficacy of tezepelumab in adolescents with severe, uncontrolled asthma

Guy Brusselle

Poster

Abstract

Inhaled corticosteroid dose reduction with tezepelumab in patients with severe, uncontrolled asthma over 2 years

Daiana Stolz

Poster

Abstract

PERSISTENCE OF EOSINOPHILS IN BRONCHIAL MUCOSA BIOPSIES IN PATIENTS TREATED WITH DUPILUMAB FOR 6 MONTHS

Francesco Bini

Poster

Abstract

Initiation, response assessment and switch of antibody therapies in patients with severe asthma a survey among German specialists

Hendrik Suhling

Poster

Abstract

The clinical experience of patients with severe asthma and previous treatment with omalizumab, choosing mepolizumab in Greece.

Maria Kallieri

Poster

Abstract

Biologic treatment patterns of severe asthma patients in the EU-4 and the UK

Samantha Valliant

Poster

Abstract

An algorithm to identify patients with T2 diseases and Chronic Spontaneous Urticaria treated with biologics in outpatient care setting using a dynamic dispensing database

Jeremy Charriot

Poster

Abstract

The effect of biologicals on lung function, inflammation and asthma control in patients treated for severe eosinophilic or type-2 inflammatory asthma 4months after treatment initiation.

Peter Emil Folkersen

Poster

Abstract

Agreement and discrepancies between past prescribing decisions and future prescribing preferences: An EU outlook

Samantha Valliant

Poster

Abstract

Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study

Pietro Curci

Poster

Abstract

Treating severe IgE mediated allergic adult asthmatics with omalizumab outside the dosing table

Etienne Ceci Bonello

Poster

Abstract

Follow-up of patients with severe eosinophilic asthma receiving benralizumab for one year (gReek rEAl Life regIStry of benralizuMab: REALISM Study)

Konstantinos Samitas

Poster

Abstract

Successful steroid weaning in a severe asthma centre does not always require biologics

Emma Graham

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}